Human Vaccines & Immunotherapeutics最新文献

{"title":"Herpes zoster vaccination and vaccine preferences among persons aged 50-64 years in Australia: Findings from a discrete choice experiment.","authors":"Sumitra Shantakumar, John Litt, Robert Booy, Lawrence Vandervoort, Vince Grillo, Emma Bandy, Raunak Parikh","doi":"10.1080/21645515.2025.2550102","DOIUrl":"https://doi.org/10.1080/21645515.2025.2550102","url":null,"abstract":"<p><p>Vaccine-preventable herpes zoster (HZ) poses substantial burden among Australian adults ≥50 years of age (YOA) despite available vaccination. This study aimed to understand the HZ vaccine-related preferences of adults paying out-of-pocket for HZ vaccination, to facilitate targeted recommendations by physicians and ultimately reduce disease burden. A discrete choice experiment was conducted (March-May 2023) to quantify preferences for HZ vaccine attributes among adults 50-64 YOA: HZ-naïve with selected self-reported comorbidities (n = 525; each comorbidity: n = 75), HZ-naïve without comorbidities (n = 150), and current/former HZ patients (n = 150). Each choice task comprised a \"no vaccine\" option and three hypothetical HZ vaccine profiles characterized by five attributes with varying levels. Attributes and levels were identified through literature review/concept elicitation/cognitive interviews/expert opinion. The attributes that most influenced HZ vaccine choice (measured by relative importance [RI]) were recommendation by government guidelines/medical societies, then HZ lifetime risk reduction, and protection duration. HZ-naïve adults with comorbidities indicated lower RI of recommendation by government guidelines/medical societies and higher RI of HZ lifetime risk reduction than other respondents. Between HZ-naïve adults without comorbidities and HZ patients, there were no significant differences in RI of each attribute. Respondents with comorbidities, whether overall or grouped by comorbidity, shared identical top three attributes. Between HZ-naïve, HZ-vaccinated adults (n = 146) and those without vaccination (n = 529), each top three attribute (recommendation by government guidelines/medical societies, HZ lifetime risk reduction, and protection duration) showed significantly different RI (p <.001). Findings elucidate the motivations underlying HZ vaccine preferences among Australian adults 50-64 YOA, guiding physician-patient conversations about HZ vaccines.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2550102"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An active post-marketing surveillance study to evaluate the safety and immunogenicity of Zyvac TCV in healthy participants.","authors":"Sanjay Vasant Mankar, Chintan Patel, Abhishek Chavan, Ravi Modi, Lisa Sarangi, Virendra Nath Tripathi, Dillip Kumar Dash, Jai Prakash Narayan, Sunil Bandgar, N Ravi Kumar, Vinay Kumar Gill, Munish Kumar Kakkar, Monjori Mitra, Pavankumar Daultani, Ravindra Mittal, Kapil Maithal, Kevinkumar Kansagra, Deven V Parmar, Trayambak Dutta, Manish Mahajan, Samir Desai","doi":"10.1080/21645515.2025.2550085","DOIUrl":"https://doi.org/10.1080/21645515.2025.2550085","url":null,"abstract":"<p><p>Typhoid fever remains a significant public health concern in endemic regions, with increasing antimicrobial resistance heightening the need for preventive strategies such as vaccination. Zyvac-TCV, a typhoid conjugate vaccine developed by Zydus Lifesciences Ltd. is licensed for use across all age groups. This prospective, multicenter, single-arm post-marketing surveillance study evaluated the safety and immunogenicity of Zyvac TCV in 3037 healthy participants aged 6 months to 45 years, enrolled across multiple Indian centers. Each participant received a single 0.5 mL intramuscular dose. Safety was assessed through monitoring of adverse events (AEs) over a 6-month period, while immunogenicity was evaluated in a subset of 300 participants by measuring serum anti-Vi IgG antibody titers at baseline and Day 28 post-vaccination. Overall, 16.7% of participants reported AEs, predominantly mild or moderate in nature, with no serious adverse events. Immunogenicity results demonstrated a seroconversion rate of 94.7% and a significant increase in geometric mean titers from 4.5 U/mL at baseline to 1787.8 U/mL at Day 28. A post-hoc batch analysis showed consistent immunogenicity across three commercial vaccine batches. Zyvac TCV was well tolerated and elicited a strong immune response in all age groups, supporting its integration into national immunization programs in typhoid-endemic regions.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2550085"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the effectiveness of COVID-19 vaccines during a period of Omicron variant predominance among Bangladeshi population: A test-negative design measurement.","authors":"Md Taufiqul Islam, Farhana Khanam, Faisal Ahmmed, Md Nazmul Hasan Rajib, Md Ismail Hossen, Shahinur Haque, Prasanta Kumar Biswas, Shah Ali Akbar Ashrafi, Ahmed Nawsher Alam, Mallick Masum Billah, Monalisa, Mohammed Ziaur Rahman, Omar Hamza Bin Manjur, Mohammad Tanbir Habib, Mokibul Hassan Afrad, S M Shamsuzzaman, Ahmed Abu Saleh, Mostafa Aziz Sumon, Asif Rashed, Tahmina Shirin, John D Clemens, Firdausi Qadri","doi":"10.1080/21645515.2025.2518644","DOIUrl":"10.1080/21645515.2025.2518644","url":null,"abstract":"<p><p>The study was conducted to estimate the protective effectiveness (PE) of complete primary or booster dose regimens of COVID-19 vaccines deployed in Bangladesh. The study was conducted in four hospitals in Dhaka between December 30, 2021, and August 31, 2022 following a test-negative design. Patients aged ≥18 years attended with COVID-like symptoms were enrolled and tested for RT-PCR. Test-negative controls were matched to confirmed cases at a 1:1 ratio considering site, date, and age groups. Conditional logistic regression was used to estimate the PE considering the association between receipt of complete primary with or without a booster regimen and development of COVID-19 disease symptoms. Whole genome sequencing (WGS) was carried out to confirm the variants. RT-PCR positive 847 cases were matched to 847 controls. WGS of strains revealed 6% to be the Delta variant and 94% was Omicron variant. The PE conferred by receipt of complete primary regimen with or without booster dose of any vaccine revealed no significant protection (15%, 95% CI: -11 to 36, <i>p</i> = .23) against any COVID-19 disease or severe disease (14%, 95%CI: -23 to 39, <i>p</i> = .42). However, there was a protective association between receipt of complete primary regimen with or without booster dose of one mRNA vaccine (Pfizer-BioNTech) against any COVID-19 disease (88% (95% CI: 26 to 98, <i>p</i> = .023)) for the first 90 days. The analysis suggested little vaccine effectiveness during Omicron surge, with the possible exception of one mRNA-vaccine 90 days after dosing.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2518644"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4.","authors":"Yu Qiao, Wanyu Zhao, Yusen Gou, Yuwei Li, Fang Su, Rui Wang, Jiejun Wang, Haibo Zhang, Lei Sun, Feng Qian, Zishu Wang","doi":"10.1080/21645515.2025.2504776","DOIUrl":"10.1080/21645515.2025.2504776","url":null,"abstract":"<p><p>Nectin-4 has emerged as a pivotal therapeutic target for antibody-drug conjugates (ADCs), particularly in advanced urothelial carcinoma (aUC) research. Although extensive literature has been reported on Nectin-4, it is worth noting that no studies have yet systematically investigated the hotspots, cutting-edge directions, and tissue expression of this target using a combination of bibliometric analysis and bioinformatics methods. Findings reveal growing interest in Nectin-4's role in cancer immunotherapy and ADC development. Urothelial carcinoma remains the primary focus, with breast and bladder cancers gaining traction. Key research priorities include optimizing ADC safety profiles, particularly managing cutaneous adverse events. Notably, dual targeting strategies combining Nectin-4 with TROP-2 show promise for next-generation ADC therapies. The study highlights evolving clinical needs, from target validation to treatment optimization, positioning Nectin-4 as a versatile biomarker bridging multiple cancer research domains. These insights emphasize the protein's translational potential while underscoring the importance of balancing therapeutic efficacy with toxicity management in ADC development.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2504776"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult pertussis in the acellular-cell vaccine era: Comparative analysis of pertussis toxin antibodies in hospitalized patients with prolonged cough.","authors":"Mengyang Guo, Haiying Li, Qinghong Meng, Yajuan Wang, Siyu Chen, Yanhai Jia, Qian Li, Min Sun, Kaihu Yao","doi":"10.1080/21645515.2025.2521915","DOIUrl":"https://doi.org/10.1080/21645515.2025.2521915","url":null,"abstract":"<p><p>In the past two years, pertussis cases in China have reemerged, shifting from infants to older children (≥6 years). In adults, underdiagnosis is common due to symptom overlap with other cough disease and limited testing, highlighting the need for better assessment in prolonged cough cases. Residual serum samples from 589 adults hospitalized with prolonged cough (≥2 weeks) formed the case group, while 589 age-, sex-, and region-matched non-cough patients served as controls. PT-IgG levels, measured via ELISA, indicated past (≥62.5 IU/mL) or recent infection (≥100 IU/mL, within a year). PT-IgG ≥ 62.5 IU/mL was detected in 17.0% of cases vs. 2.7% of controls, and ≥100 IU/mL in 7.3% vs. 1.0%. Cases had a higher median PT-IgG (16.74 vs. 2.50 IU/mL, <i>p</i> < .001). Among cases, those aged 60-69 had the highest PT-IgG ≥62.5 IU/mL (20.6%, <i>P</i> > .05). No significant difference in PT-IgG ≥ 62.5 IU/mL was observed between males and females in either group. No patients had documented pertussis. Pneumonia and chronic obstructive pulmonary disease (COPD) were the most common comorbidities in PT-IgG ≥ 62.5 IU/mL cases (43.0% vs. 40.0%), similar to PT-IgG < 62.5 IU/mL cases (37.6% vs. 43.6%). A significant proportion of hospitalized adults with a cough ≥2 weeks have serological evidence of pertussis, which could be often misdiagnosed as pneumonia or COPD. It should be considered in differential diagnoses and confirmed with laboratory testing.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2521915"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of routine pediatric vaccination of 15-valent pneumococcal conjugate vaccine in South Korea.","authors":"Young June Choe, Yunjin Jeon, Jihyun Park, Hyesun Kim, Gyongseon Yang, Salini Mohanty, Lefteris Floros, Min Huang, Nitika Chhabra, Shalini Kumari, Jasmeet Singh, Isaya Sukarom","doi":"10.1080/21645515.2025.2515650","DOIUrl":"10.1080/21645515.2025.2515650","url":null,"abstract":"<p><p>Pneumococcal disease poses a substantial clinical and economic burden, especially among children under 5 years old. The 13-valent pneumococcal conjugate vaccine (PCV13) was first introduced in South Korea's Childhood Immunization Program in 2014. In October 2023, the Ministry of Food and Drug Safety approved the use of a 15-valent pneumococcal conjugate vaccine (PCV15) in infants, children, adolescents, and adults. The aim of this study was to evaluate the cost savings of routine vaccination with PCV15 versus PCV13 in a pediatric population in South Korea. A Markov model was adapted to estimate costs and health outcomes from a societal perspective over a 100-year time horizon. The model estimated the impact of PCV15 versus PCV13 on pneumococcal disease incidence, post-meningitis sequalae, and deaths. The effectiveness of PCV15 was extrapolated from PCV13 data. Herd immunity effects were applied. Costs and epidemiological data were obtained from published literature and the National Health Information Database. Costs were reported in 2023 Korean Won (₩) with USD ($) equivalents. Quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios were estimated. The model assumed a discount rate of 4.5%. PCV15 was projected to provide a total savings of ₩36,213,756 [$27,751] with a gain of 2 QALYs versus PCV13. Under the model assumptions, switching from PCV13 to PCV15 is a cost-saving option for South Korea's routine pediatric pneumococcal vaccination program.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2515650"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144508978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promoting HPV vaccination among adolescent girls in low-resource areas of China: A multi-centered qualitative study.","authors":"Yitong Zhu, Huike Wang, Bo Zhang, Hanyue Ding, Youlin Qiao","doi":"10.1080/21645515.2025.2521940","DOIUrl":"10.1080/21645515.2025.2521940","url":null,"abstract":"<p><p>The human papillomavirus (HPV) vaccine is a key preventive measure against cervical cancer, yet by 2022, the vaccination rate among 9-14-year-old girls in China remained only 4%. This study explores parental decision-making regarding HPV vaccination for girls in low-resource areas of China with mobile information influence. Qualitative interviews were conducted with parents (<i>n</i> = 22) from middle schools in Shanxi, Sichuan, Inner Mongolia, and Yunnan provinces using purposive sampling. Participants engaged in Health Belief Model (HBM)-based-semi-structured interviews from January to March 2024. Data was transcribed and analyzed using Haase's adaptation of Colaizzi's method. Three key themes emerged: (1) Parental protection as the primary driver-Parents' instinct to protect their daughters, combined with expanded access to online health information, reinforced their recognition of HPV vaccination as a crucial preventive measure. (2) The role of government-supported programs-Free vaccination initiatives significantly improved accessibility and affordability, fostering trust in government and scientific credibility, while collective campaigns reinforced vaccine acceptance. (3) Barriers in the mobile information era-Conflicting and unclear online information led to confusion and hesitancy. Parents expressed the need for clear, authoritative communication on vaccine safety, efficacy, age recommendations, and valency options. Government-funded vaccination programs play a vital role in the mobile era, effectively promoting HPV vaccination in low-resource areas by mitigating economic barriers, trust issues, and resource limitations. However, pervasive misinformation in the mobile era remains a barrier, highlighting the urgent need for authoritative, comprehensible health communication strategies. To promote HPV vaccination, policymakers should prioritize nationwide vaccination programs and dissemination of accurate, evidence-based public health information.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2521940"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12203860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144508979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and refinement of an online CARD (Comfort Ask Relax Distract) course for organizations and providers delivering vaccinations and other needle procedures.","authors":"Anna Taddio, Anthony N T Ilersich, C Meghan McMurtry, Kaytlin Constantin, Lucie M Bucci, Victoria Gudzak, Charlotte Logeman, Natalie Crown, Mandy Kohli, Erin Ledrew, Noni E MacDonald, Card Knowledge Translation Team","doi":"10.1080/21645515.2025.2491853","DOIUrl":"10.1080/21645515.2025.2491853","url":null,"abstract":"<p><p>The CARD system (Comfort-Ask-Relax-Distract) is an evidence-based protocol for mitigating vaccine injection-related reactions, such as pain, fear and fainting. We developed a new online CARD training course to educate organizations and providers about CARD and evaluated usability and impact on conceptual knowledge and attitudes. After an initial development phase, three iterative phases of user testing were conducted in individuals with different levels of familiarity with CARD. In the first two phases, experts and non-experts provided feedback using surveys and semi-structured interviews. In the third phase, new learners answered a knowledge test and attitudes survey. Revisions occurred throughout based on qualitative and quantitative analyses, guided by the Universal Design for Learning (UDL) framework. Thirty-one healthcare providers and trainees from 8 disciplines participated across study phases. They held positive attitudes in all components of the UDL, including engagement (e.g. perceptions of relevance and value), representation (e.g. multiple ways included to perceive information, common language), and action and expression (e.g. access to materials, interactivity). Modifications addressed feedback regarding content development, organization and expression of information, and course navigation. Phase 3 participants demonstrated knowledge and positive attitudes about CARD, including confidence and intention to use CARD. In summary, this study developed and refined an online CARD course to educate organizations and providers about CARD in a feasible way and to improve readiness for implementation. The course has the potential to improve efficiency and effectiveness of CARD implementation.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2491853"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A two-decade bibliometric analysis of tumor-associated macrophages in colorectal cancer research.","authors":"Yadi Gao, Weichen Yuan, Jiexiang Zhang, Zhiwei Wang, Wenwen Cui, Zhongan Guan","doi":"10.1080/21645515.2025.2512656","DOIUrl":"10.1080/21645515.2025.2512656","url":null,"abstract":"<p><p>Tumor-associated macrophages (TAMs), the predominant immune cells in the tumor microenvironment (TME), facilitate proliferation, invasion, metastasis, angiogenesis, chemoresistance, and immunosuppression in colorectal cancer (CRC). The mutual pathological mechanisms remain unclear, necessitating an in-depth study of the relationship between TAMs and CRC. This paper employs bibliometric methods to analyze TAMs and CRC research literature, aiming to assess current trends, evaluate the research status, and forecast future directions and emerging topics. We searched for publications published in the Web of Science Core Collection (WOSCC) database from January 1, 2001 to July 31, 2024. Following the establishment of specific search criteria for time, publication type, and language, bibliometric analysis and data visualization were conducted using Microsoft Excel, R software, VOSviewer, and CiteSpace. A total of 1,218 publications authored by 8,302 researchers across 61 countries and 1,657 institutions were analyzed. They were published in 427 journals, covering 4,451 keywords and citing 65,174 references. Keyword co-occurrence and literature co-citation analysis identified nuclear factor kappa-B, endothelial growth factor, angiogenesis, polarization, TME, immune response, programmed cell death protein 1 blockade, and metabolism as current research hotspots and trends in this field. Immune therapy and cancer-associated fibroblasts are key research areas, with the potential for further exploration of their mechanisms and targeted therapies. This paper employs bibliometric methods to comprehensively analyze and visualize research papers in TAMs and CRC. It analyzes the TAM-targeting research landscape in CRC, mapping current frontiers and translational potential to position TAMs as a promising immunotherapeutic strategy.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2512656"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness modeling for gender-neutral human papillomavirus vaccines: A systematic literature review.","authors":"Marisa Felsher, Marcie Fisher-Borne, Tufail Malik, Nita Santpurkar, Stephan Martin, Omer Zaidi, Wei Wang, Cody Palmer","doi":"10.1080/21645515.2025.2516322","DOIUrl":"10.1080/21645515.2025.2516322","url":null,"abstract":"<p><p>Gender-neutral vaccination (GNV) of human papillomavirus (HPV) may help reduce the transmission and incidence of HPV-related diseases. However, approximately 40 countries have implemented HPV GNV schedules. We systematically evaluated HPV GNV cost-effectiveness models from January 2008 to May 2024 using MEDLINE, Embase, and Cochrane to identify key drivers of cost-effectiveness results. Fifty-three publications were included, primarily from high-income countries. Vaccine coverage, price, protection duration, and discount rates impacted cost-effectiveness, with lower prices and protection against HPV-related diseases resulting in cost-effective results. Results in models that included adults (≥18 years) were mixed and dependent on price, inclusion of non-cervical HPV-related diseases, and age groups considered. We conclude that HPV GNV can be a cost-effective strategy for preventing HPV-related diseases. However, its cost-effectiveness is highly dependent on vaccine coverage, price, and inclusion of non-cervical HPV-related diseases in models. Further economic evaluations of HPV GNV in low- and middle-income countries are recommended.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2516322"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}